127 related articles for article (PubMed ID: 38181814)
1. [SARS-CoV-2 Exposure and Seroprevalence of SARS-CoV-2 Antibodies among Medical Students in the First Phase of the Pandemic 2020-2021].
Landmesser P; Weissbrich B; Peter-Kern M; Krone M; Liese JG; Streng A
Gesundheitswesen; 2024 Apr; 86(4):311-314. PubMed ID: 38181814
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
3. The Seroprevalence of SARS-CoV-2 Antibodies among HealthCare Workers in University Hospital in Krakow before the Era of Vaccination.
Żółtowska B; Barańska I; Jachowicz E; Sydor W; Maziarz B; Mydel K; Różańska A; Wizner B; Rosiński J; Kossowska M; Głomb K; Wójkowska-Mach J
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409727
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021.
Ulivieri A; Morgante A; Magi F; Salehi LB; Lavra L
Epidemiol Prev; 2022; 46(5-6):367-375. PubMed ID: 36628641
[TBL] [Abstract][Full Text] [Related]
5. Antibody tests for identification of current and past infection with SARS-CoV-2.
Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
[TBL] [Abstract][Full Text] [Related]
6. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
7. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
Ladoire S; Rederstorff E; Goussot V; Parnalland S; Briot N; Ballot E; Truntzer C; Ayati S; Bengrine-Lefevre L; Bremaud N; Coudert B; Desmoulins I; Favier L; Fraisse C; Fumet JD; Hennequin A; Hervieu A; Ilie S; Kaderbhai C; Lagrange A; Martin N; Mazilu I; Mayeur D; Palmier R; Simonet-Lamm AL; Vincent J; Zanetta S; Arnould L; Coutant C; Bertaut A; Ghiringhelli F
Eur J Cancer; 2022 Apr; 165():13-24. PubMed ID: 35189537
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy.
Poletti P; Tirani M; Cereda D; Guzzetta G; Trentini F; Marziano V; Toso C; Piatti A; Piccarreta R; Melegaro A; Andreassi A; Gramegna M; Ajelli M; Merler S
JAMA Netw Open; 2021 Jul; 4(7):e2115699. PubMed ID: 34228126
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique.
Benoni R; Casigliani V; Zin A; Giannini D; Ronzoni N; Di Chiara C; Chhaganlal K; Donà D; Merolle A; Dos Anjos HG; Chenene F; Tognon F; Putoto G; Giaquinto C
BMC Infect Dis; 2023 Nov; 23(1):809. PubMed ID: 37978353
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
Front Public Health; 2022; 10():967447. PubMed ID: 36276377
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.
Bryan A; Tatem K; Diuguid-Gerber J; Cooke C; Romanoff A; Choudhury N; Scanlon M; Kishore P; Sydney E; Masci J; Bakshi P; Pemmasani S; Davis NJ; Maru D
BMJ Open; 2021 Nov; 11(11):e053158. PubMed ID: 34732494
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
Fuereder T; Berghoff AS; Heller G; Haslacher H; Perkmann T; Strassl R; Berger JM; Puhr HC; Kreminger J; Moik F; Schubert L; Starzer AM; Steindl A; Winkler S; Preusser M; Tobudic S
ESMO Open; 2020 Sep; 5(5):e000889. PubMed ID: 32878898
[TBL] [Abstract][Full Text] [Related]
15. Measuring the clustering effect of the SARS-CoV-2 transmission in a school population: a cross-sectional study in a high incidence region.
Severo M; Meireles P; Ribeiro AI; Morais V; Barros H
Sci Rep; 2023 Sep; 13(1):16300. PubMed ID: 37770455
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.
de Visscher N; Holemans X; Gillain A; Kornreich A; Lagasse R; Piette P; Ventura M; Thys F
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891515
[No Abstract] [Full Text] [Related]
18. High anti-SARS-CoV-2 antibody seroprevalence in healthcare workers in an Irish university teaching hospital.
Leonard A; Prior AR; Reilly P; Murray C; Brien MO; Maguire G; Ennis D; Reid A; Rakovac A; Boran G
Ir J Med Sci; 2022 Jun; 191(3):1023-1028. PubMed ID: 34195921
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon.
Essomba RG; Bayibeki AN; Lissom A; Ateba PT; Seni N; Fouda CAN; Mbitock SBD; Ebonda ND; Afana SD; Akame S; Tembu AA; Ngamaleu MR; Bimai BCB; Kabo O; Nguwoh PS; Ngounouh CT; Meka MCJ; Kengne M; Likeng JN; Kimessoukie EO; Nkoum BA; Assoumou MCO; Fokam J; Yap Boum II; Ambomo MS; Chadou MJP
Influenza Other Respir Viruses; 2023 Nov; 17(11):e13222. PubMed ID: 37964992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
